Drug Trial Radar · NCT06640517
Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Aug 8, 2024
Primary completion
Jun 2026
Study completion Feb 2028
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm comparison.
Conditions
- Plaque Psoriasis
Interventions
NetakimabDrug
netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
PlaceboDrug
placebo will be administered subcutaneously at a scheme masking netakimab treatment
AdalimumabDrug
adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving PASI75Time frame: Week 12
- Proportion of subjects achieving sPGA0/1Time frame: Week 12
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation
Barnaul, Russia
State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"
Chelyabinsk, Russia
Limited Liability Company "Health Azbuka Medical Center"
Kazan', Russia
State Autonomous Healthcare Institution "Republic Clinical Dermatovenerologic Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor Ge"
Kazan', Russia
State Autonomous Healthcare Institution "Kuzbass Clinical Dermatovenerological Dispensary"
Kemerovo, Russia
Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation
Kirov, Russia
State budgetary healthcare institution "Clinical Dermatovenerologic Dispensary" of the Ministry of Health of the Krasnodar Territory
Krasnodar, Russia
Federal State Autonomous Institution "National Medical Research Center for Children's Health" of the Ministry of Health of the Russian Federation
Moscow, Russia
Federal State Budgetary Institution "State scientific centre of dermatovenerology and cosmetology" of the Ministry of health of Russian Federation, Nizhny Novgorod branch
Nizhny Novgorod, Russia
Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation
Saint Petersburg, Russia
Limited Liability Company "PiterKlinika"
Saint Petersburg, Russia
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation
Tomsk, Russia
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University"
Tomsk, Russia
State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"
Yekaterinburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.